These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 23141911

  • 1. Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.
    Tichenor MS, Keith JM, Jones WM, Pierce JM, Merit J, Hawryluk N, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Wilson SJ, Wennerholm ML, Woestenborghs F, Beerens D, Luo L, Brown SM, Boeck MD, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7357-62. PubMed ID: 23141911
    [Abstract] [Full Text] [Related]

  • 2. The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.
    Keith JM, Tichenor MS, Apodaca RL, Xiao W, Jones WM, Seierstad M, Pierce JM, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Wennerholm ML, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2016 Jul 01; 26(13):3109-3114. PubMed ID: 27189675
    [Abstract] [Full Text] [Related]

  • 3. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM, Jones W, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm M, Chang L, Rizzolio M, Rynberg R, Chaplan S, Guy Breitenbucher J.
    Bioorg Med Chem Lett; 2020 Oct 15; 30(20):127463. PubMed ID: 32784090
    [Abstract] [Full Text] [Related]

  • 4. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
    Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2492-6. PubMed ID: 21392988
    [Abstract] [Full Text] [Related]

  • 5. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
    Roughley SD, Browne H, Macias AT, Benwell K, Brooks T, D'Alessandro J, Daniels Z, Dugdale S, Francis G, Gibbons B, Hart T, Haymes T, Kennett G, Lightowler S, Matassova N, Mansell H, Merrett A, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Simmonite H, Tan K, Walls SB, Wong M.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):901-6. PubMed ID: 22209458
    [Abstract] [Full Text] [Related]

  • 6. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL, Bowen SJ, Schweitzer BA, Madsen HM, McDonald J, Pelc MJ, Tenbrink RE, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5970-4. PubMed ID: 19765986
    [Abstract] [Full Text] [Related]

  • 7. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
    Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6793-6. PubMed ID: 19850474
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
    Morera L, Labar G, Ortar G, Lambert DM.
    Bioorg Med Chem; 2012 Nov 01; 20(21):6260-75. PubMed ID: 23036333
    [Abstract] [Full Text] [Related]

  • 12. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S, Simone CD, Dallavalle S, Fezza F, Nannei R, Battista N, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, Cabri W, Penco S, Merlini L, Maccarrone M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4406-11. PubMed ID: 20591666
    [Abstract] [Full Text] [Related]

  • 13. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
    Seierstad M, Breitenbucher JG.
    J Med Chem; 2008 Dec 11; 51(23):7327-43. PubMed ID: 18983142
    [No Abstract] [Full Text] [Related]

  • 14. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2011 Nov 01; 21(21):6545-53. PubMed ID: 21924613
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
    Kodani SD, Bhakta S, Hwang SH, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD.
    Bioorg Med Chem Lett; 2018 Feb 15; 28(4):762-768. PubMed ID: 29366648
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
    Kono M, Matsumoto T, Kawamura T, Nishimura A, Kiyota Y, Oki H, Miyazaki J, Igaki S, Behnke CA, Shimojo M, Kori M.
    Bioorg Med Chem; 2013 Jan 01; 21(1):28-41. PubMed ID: 23218778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.